Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial

被引：0
|
作者：
Masatoshi Kudo
Takuji Okusaka
Kenta Motomura
Izumi Ohno
Manabu Morimoto
Satoru Seo
Yoshiyuki Wada
Shinpei Sato
Tatsuya Yamashita
Masayuki Furukawa
Takeshi Aramaki
Seijin Nadano
Kazuyoshi Ohkawa
Hirofumi Fujii
Toshihiro Kudo
Junji Furuse
Hiroki Takai
Gosuke Homma
Reigetsu Yoshikawa
Andrew X. Zhu
机构：
[1] Kindai University Faculty of Medicine,Department of Gastroenterology and Hepatology
[2] National Cancer Center Hospital,Graduate School of Medicine
[3] Aso Iizuka Hospital,Graduate School of Medicine
[4] National Cancer Center Hospital East,Graduate School of Medicine
[5] Kanagawa Cancer Center,undefined
[6] Kyoto University,undefined
[7] National Hospital Organization Kyushu Medical Center,undefined
[8] Kyoundo Hospital,undefined
[9] Sasaki Institute,undefined
[10] Kanazawa University,undefined
[11] National Hospital Organization Kyushu Cancer Center,undefined
[12] Shizuoka Cancer Center Hospital,undefined
[13] National Hospital Organization Shikoku Cancer Center,undefined
[14] Osaka International Cancer Institute,undefined
[15] Jichi Medical University,undefined
[16] Osaka University,undefined
[17] Kyorin University Faculty of Medicine,undefined
[18] Eli Lilly Japan K.K.,undefined
[19] Massachusetts General Hospital Cancer Center,undefined
[20] Harvard Medical School,undefined
来源：
Journal of Gastroenterology | 2020年 / 55卷
关键词：
Alpha-fetoprotein; Hepatocellular carcinoma; Japanese subanalysis; Ramucirumab; VEGFR2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：627 / 639
页数：12
相关论文
共 50 条
  • [21] Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2
    Galle, Peter
    Kudo, Masatoshi
    Llovet, Josep M.
    Finn, Richard
    Karwal, Mark
    Denis, Pezet
    Kim, Tae-You
    Yang, Tsai-Sheng
    Zagonel, Vittorina
    Tomasek, Jiri
    Phelip, Jean-Marc
    Touchefeu, Yann
    Koh, Su-Jin
    Stirnimann, Guido
    Wang, Chunxiao
    Ogburn, Kenyon
    Abada, Paolo B.
    Widau, Ryan
    Zhu, Andrew
    JOURNAL OF HEPATOLOGY, 2020, 73 : S386 - S387
  • [22] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: interim results from an expansion cohort of the phase 3 REACH-2 study
    De Toni, E. N.
    Finn, R. C.
    Yau, Chung Cheung T.
    Yen, C. -J.
    Hsu, C. -H.
    Chan, S. L.
    He, A. R.
    Galle, P.
    Trojan, J.
    Stirnimann, G.
    Baron, A.
    Acosta-Rivera, M.
    Goyal, L.
    Wang, C.
    Abada, P.
    Widau, R.
    Zhu, A. X.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 126
  • [23] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)
    Zhu, A. X.
    Finn, R. S.
    Galle, P. R.
    Llovet, J. M.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Cella, D.
    Girvan, A.
    Gable, J.
    Bowman, L.
    Hsu, Y.
    Abada, P. B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 208 - 208
  • [24] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2
    Finn, Richard S.
    Yau, Thomas
    Hsu, Chih-Hung
    De Toni, Enrico N.
    Goyal, Lipika
    Galle, Peter R.
    Qin, Shukui
    Rao, Sujata
    Sun, Fangfang
    Wang, Chunxiao
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [25] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first line sorafenib: Pooled efficacy and safety in Chinese patients across two global randomized phase 3 studies (REACH-2 and REACH).
    Shao, Guoliang
    Bai, Yuxian
    Chen, Xiaoming
    Gu, Shanzhi
    Gu, Kangsheng
    Yuan, Xianglin
    Widau, Ryan C.
    Zhang, Wanli
    Zhang, Qiang
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16081 - E16081
  • [26] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
    Zhu, A.
    Finn, R.
    Galle, P.
    Llovet, J.
    Blanc, J. F.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Andrew X. Zhu
    Richard S. Finn
    Yoon-Koo Kang
    Chia-Jui Yen
    Peter R. Galle
    Josep M. Llovet
    Eric Assenat
    Giovanni Brandi
    Kenta Motomura
    Izumi Ohno
    Bruno Daniele
    Arndt Vogel
    Tatsuya Yamashita
    Chih-Hung Hsu
    Guido Gerken
    John Bilbruck
    Yanzhi Hsu
    Kun Liang
    Ryan C. Widau
    Chunxiao Wang
    Paolo Abada
    Masatoshi Kudo
    British Journal of Cancer, 2021, 124 : 1388 - 1397
  • [28] Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
    Zhu, Andrew X.
    Finn, Richard S.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Motomura, Kenta
    Ohno, Izumi
    Daniele, Bruno
    Vogel, Arndt
    Yamashita, Tatsuya
    Hsu, Chih-Hung
    Gerken, Guido
    Bilbruck, John
    Hsu, Yanzhi
    Liang, Kun
    Widau, Ryan C.
    Wang, Chunxiao
    Abada, Paolo
    Kudo, Masatoshi
    BRITISH JOURNAL OF CANCER, 2021, 124 (08) : 1388 - 1397
  • [29] Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
    Personeni, Nicola
    Bozzarelli, Silvia
    Pressiani, Tiziana
    Rimassa, Lorenza
    Tronconi, Maria Chiara
    Sclafani, Francesco
    Carnaghi, Carlo
    Pedicini, Vittorio
    Giordano, Laura
    Santoro, Armando
    JOURNAL OF HEPATOLOGY, 2012, 57 (01) : 101 - 107
  • [30] Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
    Ian Chau
    Joon Oh Park
    Baek-Yeol Ryoo
    Chia-Jui Yen
    Ronnie Poon
    Davide Pastorelli
    Jean-Frédéric Blanc
    Masatoshi Kudo
    Tulio Pfiffer
    Etsuro Hatano
    Hyun Cheol Chung
    Katerina Kopeckova
    Jean-Marc Phelip
    Giovanni Brandi
    Shinichi Ohkawa
    Chung-Pin Li
    Takuji Okusaka
    Yanzhi Hsu
    Paolo B. Abada
    Andrew X. Zhu
    British Journal of Cancer, 2018, 119 : 19 - 26
12345